JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study

Abstract

Background: Bladder cancer is the most common urological malignancy. Bladder cancer has limited therapeutic options, especially in advanced stages. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising target for cancer therapy. However, the role of autophagy in modulating ferroptosis remains incompletely understood.

Methods: We investigated the anti-tumor effects of JS-K, a nitric oxide-releasing prodrug, in bladder cancer through integrated cell, animal, and patient data studies. In vitro experiments with T24 and UM-UC-3 cells were used to explore how JS-K influences cancer cell survival and the interplay between autophagy and ferroptosis. In vivo, a BALB/c nude mouse tumor model provided a system to examine tumor response and tissue-level changes. To extend these findings to the clinical setting, we analyzed LC3B expression and its associations with ferroptosis-related genes, patient prognosis, and the tumor immune microenvironment.

Results: JS-K induced mitochondrial damage, lipid peroxidation, reactive oxygen species accumulation, and intracellular iron overload in bladder cancer cells in a concentration-dependent manner. These changes were accompanied by downregulation of GPX4 and SLC7A11 and upregulation of FTH1 and TFR1, indicative of ferroptosis. Inhibition or knockdown of the autophagy marker LC3B reversed these effects, establishing the role of autophagy in mediating ferroptosis. In xenograft models, JS-K suppressed tumor growth, an effect abrogated by LC3B silencing. Integrated transcriptomic and single-cell analyses revealed a strong correlation between LC3B and ferroptosis-related genes, with CISD1 identified as a key prognostic marker.

Conclusions: JS-K induces autophagy-dependent ferroptosis in bladder cancer cells and significantly suppresses tumor progression. Targeting the autophagy-ferroptosis axis offers a novel therapeutic strategy for bladder cancer treatment.

Keywords

bladder cancer / ferroptosis / autophagy / JS-K / GPX4 / CISD1

References

[1] Dyrskjot L, Hansel DE, Efstathiou JA et al. Bladder cancer. Nat Rev Dis Primers 2023; 9:58. https://doi.org/10.1038/s41572-023-00468-9.

[2] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12-49. https://doi.org/10.3322/caac.21820.

[3] Lopez-Beltran A, Cookson MS, Guercio BJ et al. Advances in diagnosis and treatment of bladder cancer. BMJ 2024; 384:e076743. https://doi.org/10.1136/bmj-2023-076743.

[4] Al Hussein Al Awamlh B, Chang SS. Novel therapies for high-risk non-muscle invasive bladder cancer. Curr Oncol Rep 2023; 25:83-91. https://doi.org/10.1007/s11912-022-01350-9.

[5] Li R, Naidu S, Fan W et al. Effec tiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol 2023; 41:457.e17-24. https://doi.org/10.1016/j.urolonc.2023.09.017.

[6] Brocklehurst A, Varughese M, Birtle A. Bladder preservation for muscle-invasive bladder cancer with variant histology. Semin Radiat Oncol 2023; 33:62-9. https://doi.org/10.1016/j.semradonc.2022.10.008.

[7] Basile G, Bandini M, Gibb EA et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscleinvasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res 2022; 28:5107-14. https://doi.org/10.1158/1078-0432.CCR-22-2158.

[8] Zhong H, Lai Y, Ouyang W et al. Integrative analysis of cuproptosis-related lncRNAs: unveiling prognostic significance, immune microenvironment, and copper-induced mechanisms in prostate cancer. Cancer Pathog Ther 2024; 3:48-59. https://doi.org/10.1016/j.cpt.2024.03.004.

[9] Cheng B, Tang C, Xie J et al. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis. Life Sci 2023; 325:121659. https://doi.org/10.1016/j.lfs.2023.121659.

[10] Stockwell BR, Friedmann Angeli JP, Bayir H et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017; 171:273-85. https://doi.org/10.1016/j.cell.2017.09.021.

[11] Zeng F, Nijiati S, Tang L et al. Ferroptosis detection: from approaches to applications. Angew Chem Int Ed 2023; 62:e202300379. https://doi.org/10.1002/anie.202300379.

[12] Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol 2020; 30:478-90. https://doi.org/10.1016/j.tcb.2020.02.009.

[13] Dixon SJ, Lemberg KM, Lamprecht MR et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149:1060-72. https://doi.org/10.1016/j.cell.2012.03.042.

[14] Qiu M, Chen L, Tan G et al. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells. Sci Rep 2015; 5:15104. https://doi.org/10.1038/srep15104.

[15] Liu Z, Xu Y, Zhang W et al. Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics. Sci Rep 2021; 11:10381. https://doi.org/10.1038/s41598-021-90001-3.

[16] Maciag AE, Chakrapani H, Saavedra JE et al. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo : involvement of reactive oxygen species. J Pharmacol Exp Ther 2011; 336:313-20. https://doi.org/10.1124/jpet.110.174904.

[17] Liu B, Huang X, Li Y et al. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer. BMC Cancer 2019; 19:645. https://doi.org/10.1186/s12885-019-5619-z.

[18] Zhao Y, Lin S, Zeng W et al. JS-K activates G2/M checkpoints through the DNA damage response and induces autophagy via CAMKK β/AMPK α/mTOR pathway in bladder cancer cells. J Cancer 2024; 15:343-55. https://doi.org/10.7150/jca.86393.

[19] Zhang C, Liu X, Jin S et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 2022; 21:47. https://doi.org/10.1186/s12943-022-01530-y.

[20] Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer 2019; 19:405-14. https://doi.org/10.1038/s41568-019-0149-1.

[21] Chen JJ, Galluzzi L. Fighting resilient cancers with iron. Trends Cell Biol 2018; 28:77-8. https://doi.org/10.1016/j.tcb.2017.11.007.

[22] Zhou Q, Meng Y, Li D et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Sig Transduct Target Ther 2024; 9:55. https://doi.org/10.1038/s41392-024-01769-5.

[23] Liu X, Tuerxun H, Zhao Y et al. Crosstalk between ferroptosis and autophagy: broaden horizons of cancer therapy. J Transl Med 2025; 23:18. https://doi.org/10.1186/s12967-024-06059-w.

[24] Chen F, Cai X, Kang R et al. Autophagy-dependent ferroptosis in cancer. Antioxid Redox Signaling 2023; 39:79-101. https://doi.org/10.1089/ars.2022.0202.

[25] Cuprych-Belter M, Łupicka-Słowik A, Anisiewicz A et al. Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines. Cancer Drug Resist 2025; 8:49. https://doi.org/10.20517/cdr.2025.95.

[26] Liu K, Zhu J, Song Y-X et al. Thermal intravesical chemotherapy reduce recurrence rate for non-muscle invasive bladder cancer patients: a meta-analysis. Front Oncol 2020; 10:29. https://doi.org/10.3389/fonc.2020.00029.

[27] Liu L, Huang Z, Chen J et al. Protein phosphatase 2A mediates JS-K-induced apoptosis by affec ting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells. J Cell Biochem 2018; 119:6633-43. https://doi.org/10.1002/jcb.26845.

[28] Zhao X, Cai A, Peng Z et al. JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer. J Cellular Molecular Medi 2019; 23:2489-504. https://doi.org/10.1111/jcmm.14122.

[29] Song Z, Yin Y, Hao S et al. JS-K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways. Oncol Rep 2019; 41:3475-87.

[30] Kiziltepe T, Anderson KC, Kutok JL et al. JS-K has potent antiangiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol 2010; 62:145-51. https://doi.org/10.1211/jpp.62.01.0017.

[31] Bai B, Zheng Z, Zhu B et al. An Fe(III)-covalent organic framework (COF)-sorafenib nanoplatform induces chemoferroptosis for enhanced hepatocellular carcinoma immunotherapy. Materials Today Bio 2025; 34:102135. https://doi.org/10.1016/j.mtbio.2025.102135.

[32] Dong S, Zheng L, Jiang T. Loss of lactate/proton monocarboxylate transporter 4 induces ferroptosis via the AMPK/ACC pathway and inhibition of autophagy on human bladder cancer 5637 cell line. J Oncol 2023; 2023:2830306. https://doi.org/10.1155/2023/2830306.

[33] Ahmat Amin MKB, Shimizu A, Ogita H. The pivotal roles of the epithelial membrane protein family in cancer invasiveness and metastasis. Cancers 2019; 11:1620. https://doi.org/10.3390/cancers11111620.

[34] Ahmat Amin MKB, Shimizu A, Zankov DP et al. Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1. Oncogene 2018; 37:5416-34. https://doi.org/10.1038/s41388-018-0286-0.

[35] Liu S, Shi J, Wang L et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radical Biol Med 2022; 189:42-57. https://doi.org/10.1016/j.freeradbiomed.2022.06.247.

[36] Song Y, Du Y, Jiang S et al. Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma. Pharmacol Res 2025; 211:107543. https://doi.org/10.1016/j.phrs.2024.107543.

[37] Si J, Liang C, Zhang X et al. LINC00922: a critical oncogenic long non-coding RNA involved in cancer progression, chemotherapy resistance, and microRNA regulation. Med Adv 2025; 3:65-79. https://doi.org/10.1002/med4.70018.

[38] Sun Y, Berleth N, Wu W et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis 2021; 12:1028. https://doi.org/10.1038/s41419-021-04306-2.

[39] Hu C, Wei S, Zhu W et al. IRE1 α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer. Cancer Drug Resist 2025; 8:41. https://doi.org/10.20517/cdr.2025.119.

[40] Klionsky DJ, Abdel-Aziz AK, Abdelfatah S et al. Guidelines for the use and interpretation of assays for monitoring au-tophagy (4th edition). Autophagy 2021; 17:1-382. https://doi.org/10.1080/15548627.2020.1797280.

[41] Zhang A, Yang J, Ma C et al. Development and validation of a robust ferroptosis-related prognostic signature in lung adenocarcinoma. Front Cell Dev Biol 2021; 9:616271. https://doi.org/10.3389/fcell.2021.616271.

[42] Yuan H, Li X, Zhang X et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem Biophys Res Commun 2016; 478:838-44. https://doi.org/10.1016/j.bbrc.2016.08.034.

[43] Wang T, Xiao X, Zhang Z et al. Predictive and therapeutic value of the ferroptosis gene CISD 1 in non-small cell lung cancer. Oncol Lett 2025; 29:1. https://doi.org/10.3892/ol.2025.14981.

[44] Zang J, Cui M, Xiao L et al. Overexpression of ferroptosisrelated genes FSP1 and CISD 1 is related to prognosis and tumor immune infiltration in gastric cancer. Clin Transl Oncol 2023; 25:2532-44. https://doi.org/10.1007/s12094-023-03136-2.

[45] Lu T, Li C, Xiang C et al. Overexpression of CISD1 predicts worse survival in hepatocarcinoma patients. Biomed Res Int 2022; 2022:7823191. https://doi.org/10.1155/2022/7823191.

[46] Ma Z, Guo L, Ji R et al. Pseudorabies virus induces ferroptosis by disrupting iron homeostasis through activation of TfR1 and ferritinophagy. J Virol 2025; 99:e0097425. https://doi.org/10.1128/jvi.00974-25.

[47] Yu S, Qin Z, Chen Y et al. Antimony-induced hippocampal neuronal impairment through ferroptosis activation from NCOA4-mediated ferritinophagy. Chem Biol Interact 2025; 409:111415. https://doi.org/10.1016/j.cbi.2025.111415.

[48] Kong N, Chen X, Feng J et al. Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B 2021; 11:4045-54. https://doi.org/10.1016/j.apsb.2021.03.036.

[49] Liu L, Liu R, Liu Y et al. Cystine-glutamate antiporter xCT as a therapeutic target for cancer. Cell Biochem Funct 2021; 39:174-9. https://doi.org/10.1002/cbf.3581.

[50] Tan M, Yin Y, Chen W et al. Trimetazidine attenuates ischemia/reperfusion-induced myocardial ferroptosis by modulating the Sirt3/Nrf2-GSH system and reducing oxidative/ nitrative stress. Biochem Pharmacol 2024; 229:116479. https://doi.org/10.1016/j.bcp.2024.116479.

[51] Zhou H, Liu Y, Shi F et al. CLK2 regulates the KEAP1/NRF2 and p53 pathways to suppress ferroptosis in colorectal cancer. Cancer Res 2025; 85:4734-50. https://doi.org/10.1158/0008-5472.CAN-24-4949.

[52] Wang Q, Ke S, Liu Z et al. HSPA5 promotes the proliferation, metastasis and regulates ferroptosis of bladder cancer. Int J Mol Sci 2023; 24:5144. https://doi.org/10.3390/ijms24065144.

[53] Zhai X, Lin Y, Zhu L et al. Ferroptosis in cancer immunity and immunotherapy: multifaceted interplay and clinical implications. Cytokine Growth Factor Rev 2024; 75:101-9. https://doi.org/10.1016/j.cytogfr.2023.08.004.